Author

Sabine Karolus

German Cancer Research Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Approach:experimental assay· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Angelika Wörner· 2 shared Cindy KörneriD· 2 shared Janina MülleriD· 2 shared Luisa E. SchwarzmülleriD· 2 shared Sara Burmester· 2 shared Stefan WiemanniD· 2 shared Almut SchulzeiD· 1 shared Birgitta E. MichelsiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Angelika Wörner

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyMolecular OncologyPeer-reviewedJun 5, 2026

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and Tamoxifen in a luminal A breast cancer model

Luisa E. Schwarzmüller, Janina Müller, Efstathios–Iason Vlachavas…·Stefan Wiemann

This study shows PAK1 activation leads to different resistance mechanisms against Tamoxifen and aromatase inhibitors in luminal A breast cancer by affecting apoptosis and proliferation through distinct pathways.

2 citations

humanproteomics

Cancer BiologyClinical EpigeneticsPeer-reviewedApr 29, 2026

GLYATL1 is associated with metabolic and epigenetic changes and with endocrine resistance in luminal breast cancer

Janina Müller, Emre Sofyalı, Luisa E. Schwarzmüller…·Stefan Wiemann

This study identifies GLYATL1 as a mediator of endocrine resistance in luminal breast cancer by promoting metabolic and epigenetic changes that counteract estrogen deprivation.

3 citationstop 1%

humanbulk RNA-seq